Press release – 1st December 2015

4P Pharma, SATT AxLR and IBMM have concluded a co-development agreement

 

Montpellier, December 1st 2015

 

In the context of an innovative medical drug development project for the treatment of cancers, called “Imiqualines”, the oncology-pharmaco-chemical and pharmaco-toxicological team of IBMM, SATT AxLR and 4P Pharma have concluded a co-development maturation agreement with a licensing option.

 

axlrsattp307-12cm      enscm     logo_cnrs_transparent    montpellier   4P_logo_B

 

EN: Press release 4P Pharma-SATT AxLR 011215

FR: Communiqué de presse 4P Pharma-SATT AxLR 011215 Press release 4P Pharma-SATT AxLR 011215

 

PRESS CONTACTS:

4P Pharma

Revital Rattenbach

1 rue du Professeur Calmette, 59000 Lille

revital@4p-pharma.com

Tel: +33 (0)9 50 72 97 68


Université de Montpellier

Anne Delestre
CC 07-003 Place Eugène Bataillon, 34095 Montpellier cedex 5

anne.delestre@umontpellier.fr

Tel: +33 (0)4 34 43 31 93

 

 

CNRS

Aurélie Lieuvin

1919 route de Mende, 34293 Montpellier cedex 5

aurelie.Lieuvin@dr13.cnrs.fr

Tel: +33 (0)4 67 61 35 10

 

 AxLR SATT

Franck-Léopold Erstein

1000, Avenue Agropolis, 34394 Montpellier cedex 5

fle@axlr.com

Tel: +33 (0)6 07 28 21 43

4P Pharma at BioFIT 2015

We will be attending BioFIT 2015 in Strasbourg, France, on next December 1st and 2nd.

Come and meet us there to talk about innovation and learn more about our innovative model to accelerate preclinical drug development!